214 related articles for article (PubMed ID: 27275635)
1. [Introduction to the molecular diagnostic methods of oncohematology].
Király AP; Alpár D; Fésüs V; Marosvári D; Matolcsy A; Bödör C
Magy Onkol; 2016 Jun; 60(2):88-98. PubMed ID: 27275635
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease testing in hematologic malignancies and solid cancer.
Ben Lassoued A; Nivaggioni V; Gabert J
Expert Rev Mol Diagn; 2014 Jul; 14(6):699-712. PubMed ID: 24938122
[TBL] [Abstract][Full Text] [Related]
3. [Multiplex ligation-dependent probe amplification in oncohematological diagnostics and research].
Kiss R; Kosztolányi S; Gángó A; Szuhai K; Bödör C; Alpár D
Orv Hetil; 2018 Apr; 159(15):583-592. PubMed ID: 29631426
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnostics.
Braziel RM; Shipp MA; Feldman AL; Espina V; Winters M; Jaffe ES; Petricoin EF; Liotta LA
Hematology Am Soc Hematol Educ Program; 2003; ():279-93. PubMed ID: 14633786
[TBL] [Abstract][Full Text] [Related]
5. Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.
Nyvold CG
Expert Rev Mol Diagn; 2015 May; 15(5):581-4. PubMed ID: 25676837
[TBL] [Abstract][Full Text] [Related]
6. [Minimal residual disease in hematology].
Rák K
Orv Hetil; 2001 May; 142(21):1091-5. PubMed ID: 11449837
[No Abstract] [Full Text] [Related]
7. Minimal residual disease in hematological malignancies.
Raanani P; Hochhaus A
Acta Haematol; 2004; 112(1-2):5-7. PubMed ID: 15178998
[No Abstract] [Full Text] [Related]
8. Novel precision medicine approaches and treatment strategies in hematological malignancies.
Rosenquist R; Bernard E; Erkers T; Scott DW; Itzykson R; Rousselot P; Soulier J; Hutchings M; Östling P; Cavelier L; Fioretos T; Smedby KE
J Intern Med; 2023 Oct; 294(4):413-436. PubMed ID: 37424223
[TBL] [Abstract][Full Text] [Related]
9. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
Sánchez R; Ayala R; Martínez-López J
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.
Bench AJ; Erber WN; Scott MA
Clin Lab Haematol; 2005 Jun; 27(3):148-71. PubMed ID: 15938721
[TBL] [Abstract][Full Text] [Related]
11. [Genetic analysis and immunophenotyping in the diagnosis of hematological disease].
Hergersberg M; Röthlisberger B; Heijnen IA; Huber AR
Ther Umsch; 2004 Feb; 61(2):83-91. PubMed ID: 15018391
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic methods in the diagnosis of hematologic neoplasms.
Sen F; Vega F; Medeiros LJ
Semin Diagn Pathol; 2002 May; 19(2):72-93. PubMed ID: 12036283
[TBL] [Abstract][Full Text] [Related]
13. Detection of immunoglobulin heavy chain gene rearrangements in hematologic malignancies.
Gleissner B; Thiel E
Expert Rev Mol Diagn; 2001 Jul; 1(2):191-200. PubMed ID: 11901814
[TBL] [Abstract][Full Text] [Related]
14. [Precision diagnostics and therapy in hematological malignancies].
Hellström Lindberg E; Cavelier L; Cammenga J; Andersson PO; Fioretos T; Rosenquist R
Lakartidningen; 2021 May; 118():. PubMed ID: 33973223
[TBL] [Abstract][Full Text] [Related]
15. [Molecular diagnosis and new gene engineering in hematological malignancies].
Funato T; Fujiwara J; Fujimaki S; Kaku M
Rinsho Byori; 2000 Oct; 48(10):887-91. PubMed ID: 11215098
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of molecular genetic testing in hematologic malignancies: advantages and limitations.
Bagg A
Hum Pathol; 2003 Apr; 34(4):352-8. PubMed ID: 12733115
[No Abstract] [Full Text] [Related]
17. Pitfalls in molecular diagnosis in haemato-oncology.
Mason J; Akiki S; Griffiths MJ
J Clin Pathol; 2011 Apr; 64(4):275-8. PubMed ID: 21421696
[No Abstract] [Full Text] [Related]
18. Cell-free DNA - Minimally invasive marker of hematological malignancies.
Kubaczkova V; Vrabel D; Sedlarikova L; Besse L; Sevcikova S
Eur J Haematol; 2017 Oct; 99(4):291-299. PubMed ID: 28692178
[TBL] [Abstract][Full Text] [Related]
19. [Chromosomal analysis, fluorescence in situ hybridization method, and spectral karyotyping in hematologic malignancies].
Nara N
Rinsho Byori; 2003 Jun; Suppl 126():124-30. PubMed ID: 12905952
[No Abstract] [Full Text] [Related]
20. Advances in next-generation sequencing and emerging technologies for hematologic malignancies.
Kwon R; Yeung CCS
Haematologica; 2024 Feb; 109(2):379-387. PubMed ID: 37584286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
